Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$485.42 USD

485.42
904,979

+3.15 (0.65%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp

by Zacks Equity Research

Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

PacBio (PACB) Supports SickKids With Sequencing Technology

by Zacks Equity Research

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes

by Zacks Equity Research

Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

McKesson (MCK) Up 4.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Thermo Fisher (TMO) Extends Collaboration With Symphogen

by Zacks Equity Research

Thermo Fisher's (TMO) recent extension of collaboration with Symphogen is intended to support biopharmaceutical discovery and development.

Medtronic (MDT) Gains Market Share Despite COVID Headwinds

by Zacks Equity Research

In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment.

Insulet (PODD) Product Volume Up, COVID-Led Softness Persists

by Zacks Equity Research

Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.

Henry Schein (HSIC) Expands Data Analytics to Private Practices

by Zacks Equity Research

Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.

McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.

If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

SmileDirectClub (SDC) Q4 Earnings Lag Estimates, Margin Falls

by Zacks Equity Research

SmileDirectClub (SDC) reports lower-than-expected results for the fourth quarter, issues full-year 2022 sales guidance.

Here's Why You Should Invest In Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth in its consumer-centric digital solutions.

National Vision (EYE) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.

McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

McKesson (MCK) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.